ProKidney signs agreement with Jefferies for up to $200 million at-the-market share offering

• ProKidney entered an at-the-market sales agreement with Jefferies on October 29, 2026.
• The agreement allows sales of up to $200 million in Class A common stock, subject to the shelf registration statement becoming effective.
• Jefferies will receive up to 3% of gross offering proceeds as compensation.
• The company has no obligation to sell shares and may suspend the offering at any time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-438071), on October 29, 2026, and is solely responsible for the information contained therein.